What question did this study set out to answer?

This research evaluates the effectiveness and safety of neoadjuvant immune checkpoint inhibitors in localized dMMR/MSI-H gastric cancer.

February 16, 2026Open Access

Neoadjuvant immune checkpoint inhibitors for localized dMMR/MSI-H gastric cancer: a meta-analysis

Key Points

This research evaluates the effectiveness and safety of neoadjuvant immune checkpoint inhibitors in localized dMMR/MSI-H gastric cancer.
Conducted a meta-analysis of existing studies on neoadjuvant immune checkpoint inhibitors in gastric cancer.
Analyzed efficacy and safety data, focusing on pathological complete response rates and treatment duration.
Examined the potential of organ-preserving strategies.
Neoadjuvant immune checkpoint inhibitors are linked to favorable efficacy and safety outcomes.
Longer treatment duration (≥3 months) correlates with improved pathological complete response rates.
The need for larger prospective studies is emphasized to determine optimal treatment protocols.

Abstract

Neoadjuvant ICIs are associated with favorable efficacy and safety in localized dMMR/MSI-H gastric and GEJ cancers. Longer neoadjuvant exposure (≥3 months) may improve pCR rates. Larger prospective studies are needed to define optimal treatment duration and the role of organ-preserving strategies such as NOM.

Read Full Paperexternally

Ask AI

Helpful

Bookmark

View Full Paper